Enanta Pharmaceuticals, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 10.71 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 311.93M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company’s product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
Details
| Name | Enanta Pharmaceuticals, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 120 |
| Founded | 1995 |
| Ipo Date | 2013-03-21 |
| Ceo | Jay Luly |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | October - September |
| Reporting Currency | USD |
| Isin | US29251M1062 |
| Cusip | 29251M106 |
| Cik | 0001177648 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Dr. Jay R. Luly Ph.D. | President, Chief Executive Officer and Director |
| Dr. Yat Sun Or Ph.D. | Chief Scientific Officer |
| Dr. Scott T. Rottinghaus M.D. | Chief Medical Officer |
| Harry R. Trout III | Vice President of Finance and Interim Principal Financial Officer |
| Kathleen S. Capps CPA | Executive Director of Accounting, Controller and Interim Principal Accounting Officer |
| Jennifer Viera | Executive Director of Investor Relations and Corporate Communications |
| Matthew P. Kowalsky J.D. | Chief Legal Officer and Corporate Secretary |
| Nathaniel S. Gardiner J.D. | Consultant |
| Tara Lynn Kieffer Ph.D. | Chief Product Strategy Officer |
| Brendan Luu | Chief Business Officer |
Contact
| Address | 4 Kingsbury Avenue, Watertown, Massachusetts 02472, United States |
| Phone | 617 607 0800 |
| Website | https://www.enanta.com |